

### **Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims**

1-194. (Cancelled)

195. (Previously Presented) A method of inhibiting B lymphocytes comprising administering an effective amount of an antibody that binds a protein whose amino acid sequence is:

MDDSTEREQS RLTSCLKKRE EMKLKECVSI LPRKESPSVR SSKDGKLLAA  
TLLLALLSCC LTVVSFYQVA ALQGDLASLR AELQGHHA EK LPAGAGAPKA  
GLEEAPAVTA GLKIFEPPAP GEGNSSQNSR NKRAVQGPEE TVTQDCLQLI  
ADSETPTIQK GSYTFVPWLL SFKRGSAL EE KENKILVKET GYFFIYGQVL  
YTDKTYAMGH LIQRKKVHVF GDELSLVTLF RCIQNMPETL PNNSCYSAGI  
AKLEEGDELQ LAIPRENAQI SLDGDVTFFG ALKLL

wherein B lymphocytes are inhibited.

196. (Previously Presented) A method of inhibiting B lymphocyte proliferation comprising administering an effective amount of an antibody that binds Neutrokin- $\alpha$  (SEQ ID NO:2), wherein B lymphocyte proliferation is inhibited.

197. (Previously Presented) A method of inhibiting B lymphocyte differentiation comprising administering an effective amount of an antibody that binds Neutrokin- $\alpha$  (SEQ ID NO:2), wherein B lymphocyte differentiation is inhibited.

198. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is a monoclonal antibody.

199. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is recombinantly produced.

200. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is a chimeric antibody.

201. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is a humanized antibody.

202. (Previously Presented) The method of any one of claims 195-197, wherein the antibody comprises human constant domains.

203. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is a F(ab')<sub>2</sub> fragment.

204. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is a polyclonal antibody.

205. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is a Fab fragment.

206. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is administered to an individual.

207. (Previously Presented) The method of any one of claims 195-197, wherein the antibody is administered to a cell culture.

208-221. (Cancelled)